The difference in anti-tumour efficacy can be further explained by the in silico modelling and simulations which showed that 11B12-1 interferes and blocks specifically with the heterodimer PD-1-PD-L1 receptor-ligand binding domain whilst 12F1-1 with PD-L1/PD-L1 homodimerization. This evidence concerns the gene PDCD1 and neoplasm.